trending Market Intelligence /marketintelligence/en/news-insights/trending/ylpGi3Z6RGqdMp3V7gY8qg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sapporo Clinical Laboratory fiscal Q4 profit climbs 55.8% YOY

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sapporo Clinical Laboratory fiscal Q4 profit climbs 55.8% YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal fourth quarter ended March 31 was ¥50.59 per share, a gain of 77.9% from ¥28.43 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥176.3 million, a gain of 55.8% from ¥113.1 million in the prior-year period.

The normalized profit margin climbed to 3.9% from 2.8% in the year-earlier period.

Total revenue increased 10.7% year over year to ¥4.51 billion from ¥4.08 billion, and total operating expenses grew 8.6% year over year to ¥4.24 billion from ¥3.90 billion.

Reported net income rose from the prior-year period to ¥205.0 million, or ¥58.84 per share, from ¥56.0 million, or ¥14.07 per share.

For the year, the company's normalized net income totaled ¥147.24 per share, compared with ¥146.39 per share in the prior year.

Normalized net income was ¥559.4 million, a decline from ¥582.5 million in the prior year.

Full-year total revenue rose from the prior-year period to ¥17.17 billion from ¥16.55 billion, and total operating expenses grew year over year to ¥16.30 billion from ¥15.64 billion.

The company said reported net income grew 16.2% on an annual basis to ¥573.0 million, or ¥150.83 per share, in the full year, from ¥493.0 million, or ¥123.90 per share.

As of June 26, US$1 was equivalent to ¥123.96.